1 min read
MapLight Therapeutics Posts $0.97 Q3 GAAP Loss Per Share, Beats Estimates
MapLight Therapeutics, Inc. had $463.4 million in cash, cash equivalents and investments as of Sept. 30.

MapLight Therapeutics, Inc. posted a third-quarter GAAP loss of $0.97 per share, beating estimates by $0.22.
The company had $463.4 million in cash, cash equivalents and investments as of Sept. 30, 2026.